Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) CAO David Loomis sold 1,016 shares of the business's stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $11.89, for a total transaction of $12,080.24. Following the completion of the transaction, the chief accounting officer owned 30,800 shares in the company, valued at $366,212. The trade was a 3.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Arvinas Trading Up 3.3%
Shares of NASDAQ:ARVN opened at $11.82 on Thursday. The company has a 50-day moving average price of $12.38 and a 200-day moving average price of $10.33. The company has a market cap of $759.08 million, a price-to-earnings ratio of -14.59 and a beta of 1.88. Arvinas, Inc. has a 12 month low of $5.90 and a 12 month high of $19.40.
Key Stories Impacting Arvinas
Here are the key news stories impacting Arvinas this week:
- Positive Sentiment: Upcoming catalyst — Arvinas will host a webcast to report Q4 and full‑year 2025 results on Feb. 24; that event gives management a chance to reset expectations or highlight clinical/pipeline progress, which could drive upside or increased trading volume. Arvinas to Report Q4 and Full Year 2025 Financial Results
- Neutral Sentiment: Short‑interest reporting anomaly — recent short‑interest prints show 0 shares (days‑to‑cover 0.0), which is almost certainly a data error and unlikely to reflect meaningful changes to short positioning; treat these figures cautiously.
- Neutral Sentiment: Institutional & analyst context — multiple funds have modestly adjusted positions recently and Wall Street coverage is mixed (consensus “Hold” with a ~$13.12 target); this background suggests the stock’s longer‑term view remains driven by clinical/pharma news rather than the recent micro trades. MarketBeat ARVN
- Negative Sentiment: Clustered insider selling — several senior insiders sold shares on Feb. 13 at an average price of $11.89: CEO Randy Teel (4,403 shares), CFO Andrew Saik (5,134 shares), CAO David K. Loomis (1,016 shares) and insider Noah Berkowitz (5,685 shares). While sizes are modest relative to institutional holdings, simultaneous sales by top executives often hurt near‑term sentiment and can pressure the stock. SEC filings: Loomis (Loomis Form 4), Berkowitz (Berkowitz Form 4), Saik (Saik Form 4), Teel (Teel Form 4).
Analysts Set New Price Targets
Several equities analysts have recently issued reports on ARVN shares. BTIG Research boosted their target price on Arvinas from $10.00 to $14.00 and gave the company a "buy" rating in a research note on Thursday, October 30th. Citigroup upgraded shares of Arvinas from a "neutral" rating to a "buy" rating and lifted their price target for the company from $10.00 to $15.00 in a report on Tuesday, January 6th. Wells Fargo & Company decreased their price objective on shares of Arvinas from $16.00 to $15.00 and set an "overweight" rating for the company in a report on Thursday, November 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arvinas in a research note on Monday, December 22nd. Finally, Wedbush reiterated a "neutral" rating and set a $9.00 price target on shares of Arvinas in a research report on Thursday, November 6th. Ten analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $13.12.
Read Our Latest Stock Analysis on ARVN
Institutional Trading of Arvinas
Hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its stake in shares of Arvinas by 491.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company's stock worth $43,000 after acquiring an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board grew its holdings in Arvinas by 109.4% in the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company's stock worth $49,000 after purchasing an additional 3,500 shares during the period. State of Wyoming bought a new position in shares of Arvinas during the third quarter valued at approximately $68,000. Abel Hall LLC purchased a new position in shares of Arvinas during the fourth quarter valued at approximately $125,000. Finally, Corient Private Wealth LLC bought a new stake in shares of Arvinas in the 4th quarter worth approximately $127,000. 95.19% of the stock is owned by hedge funds and other institutional investors.
About Arvinas
(
Get Free Report)
Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.
The company's most advanced clinical candidates address hormone-driven cancers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
